ClinicalTrials.gg
CompletedNCT03387787Updated Mar 16, 2023

Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2

A Phase 2/3 interventional study of GlucoTab and Insulin Degludec in Type 2 Diabetes Mellitus, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
67th of 70
15 · median 384
Started
2018
with 4 others
Phase 2/3
Only one
of the 70
Registered
59th of 70
by date
Lead sponsor
1 of 70
Insel Gruppe AG, University Hospital Bern

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 67th largest by enrollment, is one of 5 that started in 2018, is the only one in phase 2/3, and was the 59th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine.

Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of \~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®.

In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient.

The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • GlucoTab, Tresiba, Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written after being advised of every detail of the study
  • Male or female sex
  • Aged ≥ 18 years
  • Known history of diabetes of at least 90 days
  • Type 2 diabetes mellitus treated with either diet alone or any combination of oral antidiabetic agents and the absence of diabetic ketoacidosis for at least 90 days.
  • 6.5 - 10.0%

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Gestational diabetes mellitus
  • Pregnancy or currently breast-feeding women
  • Known or suspected allergy to insulin degludec and/or insulin aspart
  • Continuous parenteral nutrition
  • Participation in another trial which may in the opinion of the investigator interfere with the software algorithm
  • Any mental condition rendering the patient incapable of giving
  • Any disease or condition which in the opinion of the investigator would interfere with the trial performance and/or the physical and/or psychosocial safety of the study participant
  • Critically ill patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    GlucoTab Treatment Arm

    Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system

    Device: GlucoTab · Drug: Insulin Degludec

Interventions

  • DeviceGlucoTab

    The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days.

  • During the study, patients will be treated with basal Insulin degludec

06

What researchers measure

Primary outcomes

  1. Blood Glucose in target range in percent

    We measure mean percentage of blood glucose measurements in the target range of ≥5.6 mmol/l ≤7.8 mmol/l.

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  2. Random blood glucose <9.9 mmol/l in percent

    We measure random daily blood glucose concentrations \<9.9 mmol/l as calculated by all pre-prandial and bedtime glucose values measured ≥24 hours after start of insulin therapy

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

Secondary outcomes

  1. Number of severe hypoglycaemic episodes (defined as symptomatic or asymptomatic hypoglycaemia requiring third party help)

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  2. Number of overall hypoglycaemic episodes defined as any measurement of capillary glucose concentrations ≤3.9 mmol/l with or without symptoms related to low blood glucose, according to the current definition of the American Diabetes Association (ADA)

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  3. Number of blood glucose measurements per day

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  4. Number of missed blood glucose measurements

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  5. Number of additionally required blood glucose measurements

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  6. Correction factor insulin dose per day

    As calculated by GlucoTab

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  7. Basal factor insulin dose per day

    As calculated by GlucoTab

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  8. Bolus insulin dose per day

    As calculated by GlucoTab

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  9. Number of insulin injections per day

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  10. Number and reasons for non-performance of insulin injections per day

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  11. Adherence to the insulin dose suggestion of the GlucoTab® system

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  12. Mean daily blood glucose as calculated by pre-meal and bedtime blood glucose values: Overall and per treatment day

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  13. Mean pre-bedtime blood glucose

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  14. Mean pre-breakfast blood glucose

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  15. Mean pre-lunch blood glucose

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  16. Mean pre-dinner blood glucose

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  17. Blood glucose <2.2 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  18. Blood glucose between 2.201-<3.9 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  19. Blood glucose between 3.901-<5.5 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  20. Blood glucose between 5.501- <7.8 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  21. Blood glucose between 7.801-< 9.9 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  22. Blood glucose between 9.901-<16.6 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  23. Blood glucose ≥16.601 mmol/l in percent

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

  24. Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l

    Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)

07

Study locations

1 site
  • Division of Endocrinology, Diabetes, Clinical Nutrition & Metabolism, University Hospital Berne, Switzerland
    Berne, 3010, Switzerland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2020, 24 months.

Of 26 non-industry phase 2/3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 24 months is above that.

Counting every sponsor, half of 32 studies reached it within 22 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Jan 2, 2018
StartActual
Jan 30, 2018
Primary completionActual
Jan 30, 2020
CompletionActual
Jan 30, 2020
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03387787
Responsible party
Sponsor
First posted
Jan 2, 2018
Start date
Jan 30, 2018
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Mar 16, 2023

Study contacts

Markus Laimer, Prof. MD
principal investigator · Division of Endocrinology, Diabetes, Clinical Nutrition & Metabolism, Universitsy Hospital Bern, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion